# About Prescribed CJC-1295 — Editorial standards and sourcing > Prescribed CJC-1295 is an independent editorial project that summarizes the peer-reviewed research record on CJC-1295. We are not a clinic. We do not provide medical advice. We do not sell or distribute any product. ## What this site is Prescribed CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295, a long-acting growth hormone-releasing hormone analog developed in the early 2000s and currently not approved for any human indication. We are not a clinic. We do not employ clinicians, pharmacists, or any other healthcare staff. We do not provide medical advice. We do not manufacture, sell, or distribute any product. We are not affiliated with any vendor, manufacturer, compounding pharmacy, telehealth provider, or research-chemical supplier. Our work is editorial commentary on publicly available science. ## What 'prescribed' means in this domain name The word "prescribed" in the domain prescribedcjc1295.com is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. It signals that the site engages with CJC-1295 in its regulatory and pharmacological context: the FDA review history, the prescription-status question, the 503A compounding classification, the WADA prohibited-substance designation. CJC-1295 is not currently legally prescribable to patients in the United States. The Phase 2 development program was terminated in 2006 [7], the molecule has not been approved by the FDA for any indication, and it was not added to the Section 503A bulk drug substances list at the October and December 2024 PCAC meetings [14][15]. The domain modifier reflects that regulatory reality, observed neutrally. ## Editorial standards Every quantitative claim on this site is sourced to a primary publication or a regulatory document. The references page lists every citation with its DOI and URL. We write about what was studied, in what species, at what dose, by what route, and what was observed. We do not recommend doses for human use. We do not describe CJC-1295 as a treatment for any condition. We do not promote any specific vendor, formulation, protocol, or stack. Where the published literature is incomplete or ambiguous — most notably the never-published primary endpoints of the Phase 2 trial NCT00267527 — we say so rather than filling the gap. We do not anticipate near-term resumption of clinical development that has not been formally announced by a sponsor. If new sponsor-funded clinical research on CJC-1295 begins, we will report it when peer-reviewed publications appear, not when press releases are issued. ## Sourcing methodology The research record summarized on this site was assembled from PubMed-indexed literature, ClinicalTrials.gov registry entries, FDA Pharmacy Compounding Advisory Committee briefing materials, and the official WADA Prohibited List. We prefer primary publications to secondary summaries. We prefer regulatory documents to news coverage of regulatory events. We prefer named investigator publications to anonymous web content. Where a primary source is paywalled, we link the PubMed abstract and, where available, the PMC full-text version. Where regulatory documents are issued in PDF form, we link the official agency hosting location. We do not mirror or republish primary content; we summarize it editorially and link to the original. ## What we do not do We do not sell CJC-1295 or any other peptide. We do not refer readers to vendors. We do not host any contact form that triggers any commercial process. We do not employ clinicians and we do not offer consultations. We do not write personalized dose recommendations. We do not coach research protocols. We do not endorse specific vendors or formulations. We do not link to other domains that publish related summaries. The site stands on its own as an editorial reading of one molecule. ## References [7] ConjuChem Biotechnologies. NCT00267527 — terminated October 2006. — https://clinicaltrials.gov/study/NCT00267527 [14] FDA. October 29, 2024 PCAC Meeting — CJC-1295 briefing. FDA-2024-N-4777. — https://www.fda.gov/media/182088/download [15] FDA. December 4, 2024 PCAC follow-up briefing. — https://www.fda.gov/media/183819/download --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.